ERBB2 and cancer: We propose to find a new different classification for cardiotoxic side effects mainly based only on the types of drugs used in cancer therapy, so that we can discriminate the anthracycline-related cardiotoxicity triggered by anthracyclines or anthracycline-like drugs, ErbB2-related cardiotoxicity, due to trastuzumab or other ErbB2 inhibitors and anti-angiogenic – related cardiotoxicity (both antibodies and small molecule kinase inhibitors).